化学
前药
合理设计
体内
同位素
活性氧
癌细胞
氮芥
立体化学
体外
苯硼酸
组合化学
癌症
生物化学
癌症研究
氘
代谢物
化学合成
结构-活动关系
活性代谢物
癌症治疗
代谢途径
氧化应激
还原消去
氧化磷酸化
埃博霉素
药理学
信号转导
酶
反应中间体
作者
Eron Saxon,Dana Stambekova,Thilini Nimasha Fernando Ponnamperumage,Joseph R. Clark,Xiaohua Peng
标识
DOI:10.1021/acs.jmedchem.5c01975
摘要
Boron-based reactive oxygen species (ROS)-activated prodrugs offer a promising strategy for enhancing cancer selectivity, yet their in vivo activation remains poorly defined. We report a novel H2O2-responsive phenylboronic nitrogen mustard prodrug (10a) and its precisely deuterated analogue (10b), designed to elucidate the activation pathway of ROS-responsive agents. These isotopologues differ only in ethyl substituents─hydrogen (10a) versus deuterium (10b)─enabling isotope-resolved tracking of metabolic transformations in vivo. Co-administration of 10a and 10b in triple-negative breast cancer xenograft mice identified two metabolites, providing the first definitive in vivo evidence of oxidative deboronation as the primary activation mechanism. Prodrug 10a exhibited H2O2-inducible DNA-alkylating activity, selectively inhibited the proliferation of high ROS-expressing MDA-MB-468 cancer cells over nonmalignant MCF-10A cells, markedly suppressed tumor growth without observable toxicity. This study highlights precision deuteration as a mechanistic probe and establishes a platform for rational design and optimization of boron-based anticancer prodrugs.
科研通智能强力驱动
Strongly Powered by AbleSci AI